-
Interim Results Announcement for the six months ended 30 June 2017
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2017 (the “Period”). Key Highlights Lupuzor™: is the Company’s lead program for the potential breakthrough compound for Lupus a potential life threatening auto-immune disease • Total 11…
-
ImmuPharma initiates preparation of Lupuzor’s™ regulatory submissions
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm a further update on Lupuzor™ its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. On 21 September 2017 ImmuPharma announced that that all patients in the Company’s pivotal Phase III Lupuzor™ study had passed the…
-
Update on Lupuzor™ Pivotal Phase III Study
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. Study summary as at 15th September 2017 • 200 patients successfully recruited…
-
2017 Annual General Meeting – All Resolutions Passed
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.
-
Annual General Meeting and Investor Presentation
Update on Lupuzor™ Pivotal Phase III Study A video of the presentation will be available to view on the Company’s website from Monday 3 July 2017 at www.immupharma.co.uk/events/2017 Download the June 2017 IMM presentation
-
Notice of Annual General Meeting on 30 June 2017 at 10.30am
Notice of Annual General Meeting on 30 June 2017 at 10.30am Investor presentation to follow at 11.30am Venue: Sky Light City, 50 Basinghall Sreet, London, EC2 ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that today the Annual Report and Accounts for the year ended 31 December 2016…
-
Final Results Announcement for the twelve months ended 31 December 2016
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2016 (the “Period”). Key Highlights (including post Period review) Lupuzor™: is the Company’s lead program for the potential breakthrough compound for lupus a potential life threatening auto-immune…
-
Notification of full year results – 1st June 2017
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, confirms that it will be announcing its full year results for the year ended 31 December 2016 on Thursday 1 June 2017.
-
Update on Lupuzor™ Pivotal Phase III Study
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. Study Summary 200 patients successfully recruited and randomised (dosed) 7 Countries and…
-
Notification of Major Interest by Legal & General
ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc (“L&G”) confirming its holding in ImmuPharma of 4,446,545 million Ordinary Shares in the capital of the Company, representing 3.35% of ImmuPharma’s total voting rights figure of 132,522,985 Ordinary Shares.…
